Professor of Medicine, Massachusetts General Hospital and Harvard Medical School
Oncology
Dr. Leif W. Ellisen, MD
|
|
Give Review
Leif Ellisen practices Oncology. He went to Stanford University School of Medicine. Stanford University School of Medicine is one of the top medical schools in the US. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine Leif W. Ellisen, MD is a published MD. He published 47 publications, including: 'Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.' Leif Ellisen accepts Medicare.
Publications
- Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
- Frequency of mutations in individuals with breast Cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
- Yap Tunes Airway Epithelial Size and Architecture by Regulating the Identity, Maintenance, and Self-Renewal of Stem Cells.
- Standardized decision support in next generation sequencing reports of somatic Cancer variants.
- Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant Gliomas.
- Mutational analysis and clinical correlation of metastatic colorectal Cancer.
- Basal Cell Signaling by p63 Controls Luminal Progenitor Function and Lactation via NRG1.
- Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangioCarcinoma.
- Inactivation of the tumor suppressor WTX in a subset of pediatric Tumors.
- Mutation frequency in 15 common Cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
- BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults.
- Young adult daughters of BRCA1/2 positive mothers: What do they know about hereditary Cancer and how much do they worry?
- Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell Carcinoma.
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition.
- Prospective, high-throughput molecular profiling of human Gliomas.
- The molecular pathogenesis of head and neck squamous cell Carcinoma.
- mTOR activity under hypoxia.
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in CholangioCarcinoma Identified Through Broad-Based Tumor Genotyping.
- Notch signaling mediates p63-induced quiescence: A new facet of p63/Notch crosstalk.
- Feedback Control of p53 Translation by REDD1 and mTORC1 Limits the p53-Dependent DNA Damage Response.
- Circadian function in Cancer: Regulating the DNA damage response.
- Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell Carcinoma.
- Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
- A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity.
- PARP inhibitors in Cancer therapy: promise, progress, and puzzles.
- The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast Cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast...
- A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell Carcinoma.
- BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian Carcinoma.
- Smoking and emphysema: the stress connection.
- Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis.
- Efficacy of neoadjuvant Cisplatin in triple-negative breast Cancer.
- The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha.
- Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell Carcinoma.
- Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells.
- FOXO-regulated transcription restricts overgrowth of Tsc mutant organs.
- Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.
- The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast Cancers.
- Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.
- Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell Carcinoma.
- p63 and p73: life and death in squamous cell Carcinoma.
- p63 mediates survival in squamous cell Carcinoma by suppression of p73-dependent apoptosis.
- Growth control under stress: mTOR regulation through the REDD1-TSC pathway.
- Regulation of mTOR and cell growth in response to energy stress by REDD1.
- Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
- Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast Cancer...
- REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.
Schools
Stanford University
Brigham and Women39s Hospital
Conditions Treated
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Stanford University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1225028533 | |
| NPPES Provider LastName | ELLISEN | |
| NPPES Provider FirstName | LEIF | |
| NPPES Provider ZIPCode | 021142696 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 17.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225028533 |
| Last Name Of The Provider | ELLISEN |
| First Name Of The Provider | LEIF |
| View All |
Similar Doctors
|
|
Dr. Benjamin L. Schlechter, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth Brem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick A. Ott, MD |
|
|
Dr. James W. Mier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pankaj Bhargava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rameen Beroukhim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Rabin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juan Godinez, MD |
|
|
Dr. Jeremy S. Abramson, MD
This Doctor is OpenDoctor Recommended.
|